Torrent Pharmaceuticals has received approval from its Securities Transfer and Stakeholders Relationship Committee (STSRC) for the issuance of non-convertible debentures worth up to ₹12,500.00 crores. The committee meeting held on Monday approved the comprehensive debt fundraising initiative through private placement, marking a significant step in the pharmaceutical company's capital structure optimization strategy.

Committee Approval and Market Performance

The STSRC meeting approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures aggregating up to ₹12,500.00 crores in one or more tranches. The approval was disclosed to both BSE and NSE pursuant to Regulation 30 and Regulation 51 of SEBI Listing Regulations. Following the announcement, shares of the company ended 0.25% down at ₹3,875.10 apiece on the BSE.

Comprehensive Debenture Structure

The approved NCDs carry detailed specifications designed to attract institutional and retail investors:

Security Framework and Strategic Context

The debentures will be backed by a robust security framework to provide investor protection. The company will create a first ranking exclusive charge over designated accounts where NCD proceeds will be deposited and specified trademarks of the issuer. This security structure is designed to provide a minimum security cover of 1.10x, enhancing the investment appeal for potential subscribers.

This fundraising initiative comes after Torrent Pharma announced its acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a ₹19,500.00 crore deal. The private placement route allows the pharmaceutical company to access institutional capital efficiently while maintaining flexibility in terms and conditions.

Investment Features and Timeline

The listing on NSE's Wholesale Debt Market Segment will provide liquidity to investors, enabling secondary market trading of these instruments. The annual payment schedule for both coupon and principal offers predictable cash flows for investors. The specific tenure, allotment date, maturity date, and coupon rates will be determined and communicated at the time of issuance, providing the company with market timing flexibility.

The rights and privileges of NCD holders will be detailed in the final debenture trust deed to be executed between the company and the debenture trustee. This substantial debt fundraising positions the pharmaceutical company to pursue growth opportunities while optimizing its capital structure through non-dilutive financing.

Torrent Pharmaceuticals , a prominent player in the Indian pharmaceutical industry, has successfully redeemed Commercial Papers (CPs) worth ₹200.00 crores on their maturity date. The company made this announcement through a notification to the stock exchanges BSE and NSE on December 23, 2025.

Latest Redemption Details

The Commercial Papers, issued under ISIN: INE685A14179, were fully redeemed and repaid by Torrent Pharmaceuticals on the maturity date of December 23, 2025. This action demonstrates the company's commitment to meeting its financial obligations in a timely manner.

Regulatory Compliance

The redemption was announced pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was signed by Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals Limited, ensuring proper regulatory compliance and transparency.

Financial Implications

The successful redemption of these Commercial Papers on their maturity date reflects positively on Torrent Pharmaceuticals' liquidity management and financial health. It indicates the company's ability to honor its short-term debt obligations, which is crucial for maintaining investor confidence and financial stability.

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited is a well-established pharmaceutical company based in Ahmedabad, India. The company operates in various therapeutic segments and maintains a strong commitment to delivering quality healthcare solutions. With its registered office at Torrent House, Off Ashram Road, Ahmedabad, the company continues to demonstrate financial discipline through timely debt servicing.